Analysis of hallucinogenic constituents in Amanita mushrooms circulated in Japan.
Kenji Tsujikawa, Hiroyuki Mohri, Kenji Kuwayama, Hajime Miyaguchi, Yuko T Iwata, Akinaga Gohda, Sunao Fukushima, Hiroyuki Inoue, Tohru Kishi
Forensic Science International December 20, 2006 DOI: 10.1016/j.forsciint.2006.01.004 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Chemical analysis Peer reviewed |
|---|---|
| Sample size | 11 |
| Population | Amanita muscaria and Amanita pantherina mushrooms and extract products sold in Japan |
| Keywords | Mushroom chemistry Psychoactive substances Product adulteration Amanita mushrooms |
| Citations | 51 |
| Key points | Mushrooms sold as Amanita muscaria or Amanita pantherina contained ibotenic acid and muscimol, while extract products contained little of these but other psychoactive compounds instead. |
Abstract
The constituents of seven mushrooms sold as Amanita muscaria or Amanita pantherina (five A. muscaria and two A. pantherina) and four "extracts purported to contain A. muscaria" products that are currently circulated in Japan were determined. All mushroom samples were identified as A. muscaria or A. pantherina by macroscopic and microscopic observation. The dissociative constituents, ibotenic acid (IBO) and muscimol (MUS), were extracted with 70% methanol twice and determined by gas chromatography/mass spectrometry. The IBO (as the hydrate)/MUS contents were in the range of <10-2845ppm/46-1052ppm in the cap of A. muscaria and 188-269ppm/1554-1880ppm in the cap of A. pantherina. In the caps, these compounds had a tendency to be more concentrated in the flesh than in the cuticle. On the other hand, the IBO/MUS contents in the stem were far lower than in the caps. In the "extracts purported to contain A. muscaria" products, IBO/MUS were detected below the lower limit of calibration curve (<10ppm/<25ppm) or not detected. However, these samples contained other psychoactive compounds, such as psychoactive tryptamines (5-methoxy-N,N-diisopropyltryptamine and 5-methoxy-N,N-dimethyltryptamine), reversible monoamine oxidase inhibitors (harmine and harmaline) and tropane alkaloids (atropine and scopolamine), which were not quantified. This is the first report of the chemical analysis of Amanita mushrooms that are circulated in the drug market.
Citations in the library
Cited by 15
- Toxicological Profiles of Poisonous, Edible, and Medicinal Mushrooms Mycobiology September 1, 2014
- Fungal Hallucinogens Psilocin, Ibotenic Acid, and Muscimol Therapeutic Drug Monitoring July 12, 2013
- Toxicity of muscimol and ibotenic acid containing mushrooms reported to a regional poison control center from 2002-2016. Clinical Toxicology February 1, 2019
- Pharmacognostic, Forensic and Pharmaceutical, Organizational and Legal, Clinical and Pharmacological Multidisciplinary Study with an Assessment of Peculiarities of Circulation (Use) of Smoking Mixtures of Spices and Entheogens of Amanita Muscaria Mushroom SSP Modern Pharmacy and Medicine July 18, 2023
- Classics in Chemical Neuroscience: Muscimol. ACS Chemical Neuroscience September 18, 2024
and 10 more in the library
Cites 7
- Human Pharmacology of Ayahuasca: Subjective and Cardiovascular Effects, Monoamine Metabolite Excretion, and Pharmacokinetics Journal of Pharmacology and Experimental Therapeutics June 18, 2003
- Hallucinogens and dissociative agents naturally growing in the United States. Pharmacology & Therapeutics May 1, 2004
- Monoamine oxidase inhibitor poisoning resulting from Internet misinformation on illicit substances. Journal of Toxicology Clinical Toxicology 2004
- Pharmepéna-Psychonautics: Human intranasal, sublingual and oral pharmacology of 5-methoxy-N,N-dimethyl-tryptamine. Journal of Psychoactive Drugs 2001
- Soma siddhas and alchemical enlightenment: psychedelic mushrooms in Buddhist tradition. Journal of Ethnopharmacology October 1, 1995
and 2 more in the library